You are here

No-deal Brexit advice for radiopharmacy and nuclear medicine services

6 March, 2019

The Royal College of Radiologists (RCR) has produced a practical guide to help nuclear medicine teams plan radioisotope work in case of a no-deal Brexit.

The document was produced by the RCR alongside the British Nuclear Medicine Society and the UK Radiopharmacy Group and outlines industry updates on supplier preparedness for tracer and therapeutic radioisotope supply in the event of no-deal.

“It is advised that you liaise directly with your suppliers to find out whether you are likely to experience delays for individual products”, the document outlines.

Also emphasised is the importance of communication and supply networking between hospitals.

Product alternatives and substitutions for particular imaging procedures, key considerations for oncology teams faced with irregular supply, and case prioritisation depending on supply alterations are outlined.

“In the weeks leading up to Brexit you should consider how to prioritise requests based on clinical need, should supplies be compromised,” it explains.

You can read the full guidance document here.

The Society for Radiological Protection has issued a 'Technical Note on the UK Exit from the Euratom Treaty and European Union' to which the SCoR has contributed. The note includes content about nuclear safeguards, radiation and environmental protection legislation, medical isotope supply, movement of goods and people, and data protection.

Content tools

Accessibility controls

Text size